Neuromodulatory treatments for psychiatric disease : A comprehensive survey of the clinical trial landscape
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved..
BACKGROUND: Numerous neuromodulatory therapies are currently under investigation or in clinical use for the treatment of psychiatric conditions.
OBJECTIVE/HYPOTHESIS: We sought to catalogue past and present human research studies on psychiatric neuromodulation and identify relevant trends in this field.
METHODS: ClinicalTrials.gov (https://www.clinicaltrials.gov/) and the International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/) were queried in March 2020 for trials assessing the outcome of neuromodulation for psychiatric disorders. Relevant trials were categorized by variables such as neuromodulation modality, country, brain target, publication status, design, and funding source.
RESULTS: From 72,086 initial search results, 1252 unique trials were identified. The number of trials registered annually has consistently increased. Half of all trials were active and a quarter have translated to publications. The largest proportion of trials involved depression (45%), schizophrenia (18%), and substance use disorders (14%). Trials spanned 37 countries; China, the second largest contributor (13%) after the United States (28%), has increased its output substantially in recent years. Over 75% of trials involved non-convulsive non-invasive modalities (e.g., transcranial magnetic stimulation), while convulsive (e.g., electroconvulsive therapy) and invasive modalities (e.g., deep brain stimulation) were less represented. 72% of trials featured approved or cleared interventions. Characteristic inter-modality differences were observed with respect to enrollment size, trial design/phase, and funding. Dorsolateral prefrontal cortex accounted for over half of focal neuromodulation trial targets. The proportion of trials examining biological correlates of neuromodulation has increased.
CONCLUSION(S): These results provide a comprehensive overview of the state of psychiatric neuromodulation research, revealing the growing scope and internationalism of this field.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Brain stimulation - 14(2021), 5 vom: 27. Sept., Seite 1393-1403 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Elias, Gavin J B [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 24.11.2021 Date Revised 24.11.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.brs.2021.08.021 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM33004091X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM33004091X | ||
| 003 | DE-627 | ||
| 005 | 20231225210433.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.brs.2021.08.021 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1100.xml |
| 035 | |a (DE-627)NLM33004091X | ||
| 035 | |a (NLM)34461326 | ||
| 035 | |a (PII)S1935-861X(21)00223-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Elias, Gavin J B |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Neuromodulatory treatments for psychiatric disease |b A comprehensive survey of the clinical trial landscape |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.11.2021 | ||
| 500 | |a Date Revised 24.11.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: Numerous neuromodulatory therapies are currently under investigation or in clinical use for the treatment of psychiatric conditions | ||
| 520 | |a OBJECTIVE/HYPOTHESIS: We sought to catalogue past and present human research studies on psychiatric neuromodulation and identify relevant trends in this field | ||
| 520 | |a METHODS: ClinicalTrials.gov (https://www.clinicaltrials.gov/) and the International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/) were queried in March 2020 for trials assessing the outcome of neuromodulation for psychiatric disorders. Relevant trials were categorized by variables such as neuromodulation modality, country, brain target, publication status, design, and funding source | ||
| 520 | |a RESULTS: From 72,086 initial search results, 1252 unique trials were identified. The number of trials registered annually has consistently increased. Half of all trials were active and a quarter have translated to publications. The largest proportion of trials involved depression (45%), schizophrenia (18%), and substance use disorders (14%). Trials spanned 37 countries; China, the second largest contributor (13%) after the United States (28%), has increased its output substantially in recent years. Over 75% of trials involved non-convulsive non-invasive modalities (e.g., transcranial magnetic stimulation), while convulsive (e.g., electroconvulsive therapy) and invasive modalities (e.g., deep brain stimulation) were less represented. 72% of trials featured approved or cleared interventions. Characteristic inter-modality differences were observed with respect to enrollment size, trial design/phase, and funding. Dorsolateral prefrontal cortex accounted for over half of focal neuromodulation trial targets. The proportion of trials examining biological correlates of neuromodulation has increased | ||
| 520 | |a CONCLUSION(S): These results provide a comprehensive overview of the state of psychiatric neuromodulation research, revealing the growing scope and internationalism of this field | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Bipolar disorder | |
| 650 | 4 | |a Clinical trials | |
| 650 | 4 | |a Deep brain stimulation | |
| 650 | 4 | |a Depression | |
| 650 | 4 | |a Eating disorders | |
| 650 | 4 | |a Electroconvulsive therapy | |
| 650 | 4 | |a Neuromodulation | |
| 650 | 4 | |a Obsessive-compulsive disorder | |
| 650 | 4 | |a Post-traumatic stress disorder | |
| 650 | 4 | |a Psychiatry | |
| 650 | 4 | |a Schizophrenia | |
| 650 | 4 | |a Substance use disorders | |
| 650 | 4 | |a Transcranial electrical stimulation | |
| 650 | 4 | |a Transcranial magnetic stimulation | |
| 700 | 1 | |a Boutet, Alexandre |e verfasserin |4 aut | |
| 700 | 1 | |a Parmar, Roohie |e verfasserin |4 aut | |
| 700 | 1 | |a Wong, Emily H Y |e verfasserin |4 aut | |
| 700 | 1 | |a Germann, Jürgen |e verfasserin |4 aut | |
| 700 | 1 | |a Loh, Aaron |e verfasserin |4 aut | |
| 700 | 1 | |a Paff, Michelle |e verfasserin |4 aut | |
| 700 | 1 | |a Pancholi, Aditya |e verfasserin |4 aut | |
| 700 | 1 | |a Gwun, Dave |e verfasserin |4 aut | |
| 700 | 1 | |a Chow, Clement T |e verfasserin |4 aut | |
| 700 | 1 | |a Gouveia, Flavia Venetucci |e verfasserin |4 aut | |
| 700 | 1 | |a Harmsen, Irene E |e verfasserin |4 aut | |
| 700 | 1 | |a Beyn, Michelle E |e verfasserin |4 aut | |
| 700 | 1 | |a Santarnecchi, Emiliano |e verfasserin |4 aut | |
| 700 | 1 | |a Fasano, Alfonso |e verfasserin |4 aut | |
| 700 | 1 | |a Blumberger, Daniel M |e verfasserin |4 aut | |
| 700 | 1 | |a Kennedy, Sidney H |e verfasserin |4 aut | |
| 700 | 1 | |a Lozano, Andres M |e verfasserin |4 aut | |
| 700 | 1 | |a Bhat, Venkat |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Brain stimulation |d 2008 |g 14(2021), 5 vom: 27. Sept., Seite 1393-1403 |w (DE-627)NLM185730760 |x 1876-4754 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2021 |g number:5 |g day:27 |g month:09 |g pages:1393-1403 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.brs.2021.08.021 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2021 |e 5 |b 27 |c 09 |h 1393-1403 | ||